ArticleAllergy2019
Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy.
Article in Allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Molecular Allergology: Epitope Discovery and Its Application for Allergen-Specific Immunotherapy of Food Allergy.Clinical reviews in allergy & immunology · 2025Review
- A Phenotypically Distinct Human Th2 Cell Subpopulation Is Associated With Development of Allergic Disorders in Infancy.Allergy · 2025Article
- Dynamics of T cell subpopulations and plasma cytokines during the first year of antineoplastic therapy in patients with breast cancer: the BEGYN-1 study.Breast cancer research : BCR · 2025Article
- A dominant, pan-DR binding epitope of Der p 1 in house dust mite allergy induces tolerance in HLA-DR4 transgenic mice.Frontiers in immunology · 2025Article
- Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study.Nature communications · 2024Observational
- Lipid mediators of inhalation exposure-induced pulmonary toxicity and inflammation.Inhalation toxicology · 2024Review
- T-cell subset changes during the first year of pre-seasonal allergoid allergen-specific immunotherapy.Heliyon · 2023Article
- Indoor-air purification by photoelectrochemical oxidation mitigates allergic airway responses to aerosolized cat dander in a murine model.Scientific reports · 2023Article
- Peptide immunotherapy for aeroallergens.Allergy and asthma proceedings · 2023Article
- Article
- Review
- Clinical and immunological evaluation of cat-allergic asthmatics living with or without a cat.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Article
- Design of peptides with high affinity binding to a monoclonal antibody as a basis for immunotherapy.Peptides · 2021Article
- Peptide Allergen Immunotherapy: A New Perspective in Olive-Pollen Allergy.Pharmaceutics · 2021Review
- Article
- Review
- Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy.Allergy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundAllergen immunotherapy using synthetic peptide T-cell epitopes (Cat-PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat-allergic subjects. However, the immunological mechanisms underlying clinical benefit remain only partially understood. Since previous studies of whole allergen immunotherapy demonstrated a reduction in the frequency of allergen-specific (MHC II tetramer
methodsUsing before and after treatment samples from subjects enrolled in a randomized, double-blind, placebo-controlled trial of Cat-PAD, we employed Fel d 1 MHC II tetramers and flow cytometry to analyze the expression of chemokine receptors CCR3, CCR4, CCR5, CXCR3, and CRTh2, together with markers of memory phenotype (CD27 and CCR7) on Fel d 1-specific CD4
resultsNo statistically significant change in the frequency of Fel d 1-specific CD4
conclusionsPeptide immunotherapy with Cat-PAD does not significantly alter the frequency or phenotype of Fel d 1-CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.